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Resumo 
 
A malária é uma das doenças infecciosas com maior taxa de prevalência em todo o mundo 
estimando-se nos últimos relatórios que em 2010 3,3 mil milhões de pessoas estariam em risco 
de contrair a doença. A África subsaariana é a região com maior risco onde se registam 81% da 
totalidade dos casos e 91% das mortes causadas por malária, sendo crianças com menos de 
cinco anos e mulheres grávidas as classes mais afetadas. Esta doença é causada por um 
parasita intracelular do género Plasmodium, sendo a espécie mais perigosa para o Homem o 
Plasmodium falciparum (P. falciparum). Outras espécies como P. vivax, P. ovale, P. malariae e 
P. knowlesi também afetam hospedeiros humanos. Por outro lado, P. berghei e P. yoelii são 
espécies que têm como hospedeiro os roedores e que são vulgarmente usadas como modelos 
para o estudo da malária por apresentarem características biológicas e fisiológicas similares 
aos parasitas que infectam humanos e primatas.      
O ciclo de vida do parasita Plasmodium compreende etapas obrigatórias em dois hospedeiros, 
um mosquito e um hospedeiro mamífero. A transmissão da malária realiza-se através da picada 
de um mosquito do género Anopheles infectado por Plasmodium, mas os sintomas advêm 
apenas da fase eritrocítica da infecção onde o parasita desencadeia ciclos de replicação 
assexuada no interior de eritrócitos. A etapa que precede esta fase é assintomática mas de 
grande importância para o estabelecimento da infecção. A fase pré-eritrocítica ocorre no fígado 
onde a forma do parasita transmitida pelo mosquito, o esporozoíto, invade um hepatócito dentro 
do qual se irá desenvolver e replicar para originar milhares de merozoítos que quando 
libertados para a corrente sanguínea têm a capacidade de invadir eritrócitos.  
Uma característica interessante dos esporozoítos é a sua capacidade de locomoção em 
movimentos espirais que resultam em trilhos de proteínas deixadas pelo parasita. Esta 
motilidade é essencial para o processo de migração do parasita desde o local da picada do 
mosquito, onde é depositado na pele, até ao fígado. Uma das proteínas que constituem estes 
trilhos é uma proteína de superfície denominada circumsporozoite protein (CSP). A identificação 
desta proteína como imunodominante na proteção induzida por esporozoítos atenuados por 
radiação, juntamente com a observação de que os complexos MHC classe-I têm a capacidade 
de apresentar antigénios da CSP induzindo a activação de células T CD8+ e assim protegendo 
contra esporozoítos vivos, levou a que esta proteína tenha suscitado um interesse crescente 
por parte da comunidade científica. Vários projectos de investigação têm sido direcionados para 
a utilização desta proteína para tentar induzir imunidade e desenvolver novas vacinas contra a 
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malária. Foi ainda descrito que a apresentação dos antigénios da CSP pelo complexo MHC 
classe-I é dependente do processamento prévio da proteína no proteossoma. Para que este 
processamento aconteça é necessário que a proteína seja reconhecida e direcionada para o 
proteossoma. Este mecanismo depende da associação de moléculas de ubiquitina à proteína 
alvo num processo denominado ubiquitinação e cujo elevado grau de especificidade e 
regulação é da responsabilidade das enzimas E3-ligases. As Cullin-RING ligases (CRL) 
constituem a maior classe conhecida de E3s. Estes complexos proteicos são constituídos por 
uma proteína conservada de ligação à ubiquitina e uma proteína estrutural (Cullin) e respectivo 
adaptador. Estas últimas são variáveis e conferem especificidade de ligação ao substrato. 
Dados de análise genómica e proteómica revelaram que a expressão de três de seis complexos 
CRL (Cullin1, Cullin2, Cullin4A e respectivos adaptadores) está diminuída em células infectadas 
por Plasmodium. Deste modo, propôs-se como primeiro objectivo deste trabalho investigar o 
envolvimento das CRL na ubiquitinação da CSP, colocando como hipótese que complexos 
formados por diferentes Cullins poderão intervir de forma diferente na ubiquitinação da CSP. 
Estes resultados poderão ainda trazer novos indícios à hipótese de que o parasita é capaz de 
modular o sistema ubiquitina-proteossoma do seu hospedeiro como estratégia de evasão ao 
sistema imunitário.  
Para isso planeou-se um ensaio de pull down sobre-expressando a CSP de P. yoelii, ubiquitina 
e as várias Cullins (CUL), prosseguindo com um western blot de modo a comparar os perfis de 
poli-ubiquitinação da CSP obtidos com as várias Cullins. Deste ensaio, demonstrou-se que a 
afinidade para a ubiquitinação da CSP parecia vir principalmente da CUL1 e da CUL4B. No 
perfil da CUL1 é também notória a presença de um maior número de bandas com elevado peso 
molecular que advêm da adição consecutiva das moléculas de ubiquitina que levam à 
acumulação sucessiva de 8,5kDa ao peso molecular da CSP. De modo a confirmar a 
implicação da CUL1 na ubiquitinação da CSP, um vector com a forma dominante negativa da 
CUL1 (dnCUL1) foi sobre-expresso em paralelo à CUL1 num ensaio de pull down. Esta proteína 
mutada possui a capacidade de se ligar ao complexo mas não de o activar inibindo 
competitivamente a ubiquitinação da CSP pelo CRL formado pela CUL1. Os resultados desta 
experiência indicam que a CUL1 parece ser capaz de promover a poli-ubiquitinação da CSP em 
maior extensão do que dnCUL1. Apesar dos resultados serem apenas preliminares parecem 
trazer bons indícios do envolvimento da CUL1 na ubiquitinação da CSP. Deste modo, 
juntamente com os resultados da proteómica que demonstravam que a CUL1 era uma das 
Cullins que apareciam com expressão diminuída em células infectadas por Plasmodium, os 
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resultados parecem apoiar a hipótese de que o parasita modula o sistema ubiquitina-
proteossoma do seu hospedeiro. No entanto, será necessário continuar os estudos nesta 
direcção de forma a ser possível obter mais indícios que confirmem esta hipótese. 
No presente trabalho pretendíamos ainda avaliar a relevância que as CRL teriam para o 
Plasmodium, visto que foi descrito que os parasitas possuem todos os componentes 
necessários à ubiquitinação, com destaque para CRL funcionais. Sabe-se ainda que as CRL 
também dependem da activação por nedilação, tendo já sido identificados vários homólogos de 
proteínas como Nedd8 e a CUL1, entre outras. Evidências sugerem que este sistema de 
ubiquitinação deverá desempenhar um papel importante no desenvolvimento do parasita 
embora pouco se saiba ainda sobre esta matéria. Deste modo, propomos investigar se as CRL 
terão uma função importante para o desenvolvimento do parasita no estabelecimento da 
infecção. Para tal, usou-se um composto capaz de inibir especificamente a activação da CRL 
interferindo com o seu processo de nedilação, o MLN4924. Numa primeira abordagem, 
tentámos avaliar as repercussões do uso deste composto na fase pré-eritrocítica da infecção 
usando para isso uma estratégia baseada em luminescência para quantificar os níveis de 
infecção. Destes resultados concluímos que as concentrações de droga usadas aparentemente 
não causam efeito na infecção de Plasmodium, o que nos levou a testar também o efeito na 
fase eritrocítica da infecção. Para isso, testámos o efeito na infecção através de uma técnica de 
citometria fluxo que permite avaliar tanto os níveis de parasitémia como a maturação do 
parasita. Aparentemente, MLN4924 tem a capacidade de atrasar ou parar o desenvolvimento 
do parasita nesta fase da infecção apesar de ter que ser usado em concentrações elevadas na 
ordem do micro-molar. Estas observações revelam que as CRL serão de facto importantes para 
o desenvolvimento de Plasmodium constituindo ainda um alvo com elevada especificidade para 
o desenvolvimento de novos compostos antimaláricos.   
Este trabalho permitiu elucidar a elevada importância dos CRL e do sitema ubiquitina-
proteossoma no contexto de uma infecção por Plasmodium, demonstrando-se relevantes tanto 
para o hospedeiro como para o parasita.  
 
Palavras-chave: malária, infecção por Plasmodium, CSP, poli-ubiquitinação, CUL1  
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Abstract 
 
Malaria is one of the most prevalent infectious diseases worldwide and is caused by protozoan 
parasites of the genus Plasmodium, which are obligatory intracellular parasites with a life cycle 
that requires both mosquito and mammalian hosts. In the mammalian host, the parasite 
undergoes a silent phase during hepatocyte invasion that seems to be carried out without being 
detected by the host immune system. One of the proteins described as immunodominant in this 
stage is the circumsporozoite protein (CSP), that is involved in protection induced by 
immunization with irradiated sporozoites and can be presented as antigen by MHC class-I 
complexes being able to activate CD8+ T cells protecting against a live sporozoite challenge. 
Previous genomic and proteomic studies revealed that Cullin-RING ligases (CRL), specific 
recognition factors in the ubiquitin-proteasome system, are down-modulated in infected cells. 
Now we hypothesize that the CRLs may be involved in the ubiquitination of CSP and we will 
assess this through pull down experiments evaluating CSP ubiquitination in the presence of the 
different CRL backbones, the Cullins (CUL). The results showed different CSP poly-
ubiquitination patterns in particular using CUL1 and CUL4B. Further experiments using a 
dominant negative form of CUL1 (dnCUL1) seem to indicate that CUL1 is indeed promoting CSP 
poly-ubiquitination. Together with the proteomic data, these observations support the hypothesis 
of the modulation of the host UPS in infected cells as a Plasmodium immune-evasion strategy. 
The CRL relevance for Plasmodium development and infection activity was also investigated 
using a specific neddylation inhibitor - MLN4924. Evidences show that CRLs is important during 
Plasmodium blood stages, as MLN4924 could actively delay or arrest the parasite development. 
Although this compound is not potent enough to be used as antimalarial, it evidenced that CRL 
could represent a new specific target to try to develop new antimalarial compounds.    
 
Key-words: malaria, Plasmodium infection, CSP, poly-ubiquitination, CRL, CUL1 
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CRL: Cullin-RING ligase 
CSP: Circumsporozoite protein 
CUL: Cullin 
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dnCUL: Dominant negative Cullin 
E3: E3-Ubiquitin ligase 
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MG132:  Proteasome inhibitor 
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MHC: Major histocompatibility complex 
MLN4924: NAE inhibitor 
NAE: Nedd8 activating enzyme 
PBS: Phosphate-buffered saline 
PD: Pull down 
PFA: Paraformaldeide 
PV/ PVM: Parasitophorous vacuole; PV membrane 
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RT: Room temperature 
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TCL: Total cellular lysate 
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UPS: Ubiquitin-proteasome system 
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1. Introduction 
 
1.1. The Malaria burden 
Malaria is one of the most prevalent infectious diseases worldwide and the latest reports 
estimate that 3.3 billion people were at risk of acquiring malaria in 2010 (World Health 
Organization, 2011). Populations living in sub-Saharan Africa have the highest risks as 81% of 
cases and 91% of deaths are estimated to have occurred in this African Region (Fig.1). Young 
children under five years of age and pregnant women are the most severely affected classes 
(World Health Organization, 2011).  
 
Figure 1 - Malaria incidence worldwide. Endemic countries or areas with limited risk or with effective 
malaria transmission in the end of 2010 (World Health Organization, 2011).   
 
Malaria is caused by parasites of the genus Plasmodium that are obligatory intracellular 
protozoan parasites. The species that can cause malaria in humans are Plasmodium falciparum 
(P. falciparum), the most deadly and predominant in Africa; P. vivax, less dangerous but more 
widespread; P. ovale, P. malariae and P. knowlesi that are found less frequently. These 
parasites are transmitted to humans through the byte of an infected female mosquito of the 
genus Anopheles (World Health Organization, 2011).   
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The malaria disease is typically recognized by its cyclic patterns of fevers and chills, in most of 
the cases, but it can also lead to severe malaria that comprises syndromes like severe anaemia, 
acute respiratory distress or cerebral malaria, that are the main causes of death. This is caused 
by the rapid asexual multiplication phase of the Plasmodium parasite inside red blood cells, also 
called the blood stage infection (Silvie et al., 2008).  
Rodent malaria parasites are used as disease models for a significant amount of in vitro and in 
vivo research (Sherman, 1998). Models such as P. berghei and P. yoelii  are analogous to 
human and primate parasites in terms of biology, physiology and life cycle (Sherman, 1998). 
Besides, these parasites are not dangerous to humans representing good models for 
experimental study of mammalian malaria (Sherman, 1998).   
 
1.2. Plasmodium life cycle 
Plasmodium has a complex life cycle that involves stages in the mosquito vector and in the 
mammalian host (Fig.2). All the pathology associated to malaria is due to the blood stage of the 
infection (Fig.2(5)). In this stage, the parasite undergoes cycles of growth and asexual division 
inside the host red blood cells (RBC). The merozoite, the parasite form that invades the RBC, 
grows and matures in three successive morphological stages: ring, trophozoite and schizont 
stage, each being accompanied by specific host modifications (Bannister et al., 2000). During 
the first two stages the parasites grow and mature and it is only during the schizont stage that 
cell division occurs. After complete parasite development the RBC ruptures releasing into the 
blood stream  approximately 20 daughter merozoites that will invade new RBCs initiating a new 
infection cycle. After a few weeks of asexual cycling in the blood stream, some parasites 
develop into a highly specialized form, the gametocyte (Bannister et al., 2000; reviewed in Tilley 
et al., 2011). The uptake of gametocytes by a mosquito during a blood meal (Fig.2(6)) activates 
the formation of male and female gametes in the mosquito midgut lumen. After sexual genetic 
recombination, the parasites develop into oocysts and later sporozoites, a motile form that 
adhere to the mosquito salivary glands and is transmitted in a subsequent mosquito bite, closing 
the disease transmission cycle (Aly & Vaughan, 2009). 
The beginning of the mammalian host malaria infection occurs when a female Anopheles 
mosquito injects Plasmodium sporozoites, that are inside the salivary glands, into the skin of the 
host during its blood meal (Fig.2(1); Ponnudurai et al. 1991). Sporozoites actively migrate 
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through the skin cells until they find a blood vessel entering the blood circulation (Fig.2(2)); Mota 
et al., 2001; Silvie et al., 2008). Once in circulation, sporozoites travel and stop in the liver 
(Fig.2(3)) due to the interaction between the circumsporozoite protein (CSP), which covers the 
surface of sporozoites, with heparan sulfate proteoglicans (HSPG) on liver cells (Silvie et al., 
2008). After crossing the sinusoidal cell layer, possibly through Kupffer cells, some hepatocytes 
will also be traversed before the switch from cell traversal to productive invasion (Silvie et al., 
2008). The invasion of a last hepatocyte occurs without cell membrane rupture, instead the 
parasite forms a specialized compartment, the parasitophorous vacuole (PV) (Mota et al., 2001). 
After a productive invasion, Plasmodium sporozoites develop into an exoerythrocitic form (EEF) 
growing and replicating by schizogony into thousands of newly formed merozoites that will be 
contained inside the PV membrane (PVM) until their release into the bloodstream (Fig.2(4); 
Silvie et al., 2008). 
 
 
Figure 2 - The Plasmodium life cycle. (1)  During a blood meal of a female Anopheles mosquito, 
sporozoites contained in the salivary glands are injected into the skin of a mammalian host. The 
sporozoites enter the bloodstream and migrate to the liver (2) where they will traverse a few hepatocytes 
before invading a final one (3). The parasite will grow and replicate into thousands of merozoites that will 
be released into the blood stream (4) and initiate the blood stage cycles of asexual replication inside RBC 
(5). Some merozoites can develop as gametocytes that can be ingested by another mosquito through 
blood meal (6), leading to a new cycle of infection (adapted from Prudêncio et al. 2007).     
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An interesting feature of sporozoites is their substrate-dependent locomotion in spiral 
movements that is characterized by the trails of parasite proteins that are left behind. This 
feature, known as gliding motility, is essential for the migration process. One of the proteins 
known to form these trails and that is also found in the cytosol of traversed cells due to the 
migration process is the CSP, the most abundant surface protein on the sporozoite (Mota & 
Rodriguez, 2001). 
 
1.3. Circumsporozoite protein 
CSP is essential for sporozoite development. It uniformly covers their surface and is attached to 
the plasma membrane through a GPI anchor (Wang et al., 2005). CSP is also expressed on 
plasma membranes of EEFs (Hollingdale et al., 1983). Two highly conserved motifs are found 
among all malaria species, regions I and II, located at the amino- and carboxyl-terminal of the 
molecule, respectively, and a central repeat region. C-terminal region is composed by the GPI 
anchor and a type I thrombospondin repeat (TSR) that is essential for sporozoite motility, 
salivary gland invasion and hepatocyte infection (Aly & Vaughan, 2009; Tewari et al, 2002).  
Due to the trails left behind during migration, CSP is found in large amounts which creates the 
potential for the development of an immune response towards this protein (Overstreet et al., 
2008). Antibodies specific for CSP as well as CD8+ T cell clones for CSP antigens have been 
shown to be involved in protective mechanisms that result in inhibition of sporozoite infectivity 
and EEF killing (Romero et al., 1989; Kumar et al., 2006; reviewed in Overstreet et al., 2008). 
Thus, CSP has been the primary target of research to try to induce protective immunity either 
with synthetic subunit vaccines or bacterial and viral vectors encoding Plasmodium CSP 
(reviewed in Overstreet et al., 2008). One of the most successful vaccine candidate until now is 
the RTS,S that was the first malaria vaccine candidate to reach large-scale phase III clinical 
trials testing (Agnandji et al., 2011). 
Previous work using murine models has shown that CSP can be processed and antigens 
presented in both infected and traversed primary hepatocytes in the context of MHC class-I 
complex (Bongfen et al., 2007). Furthermore, these antigens that are able to stimulate CD8+ T 
cells mounting a protective immune response, are generated by the proteasome (Bongfen et al., 
2007). 
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1.4. MHC class-I presentation and the Ubiquitin-Proteasome system 
The Ubiquitin-proteasome system (UPS) is responsible for the generation of small peptides that 
will be associated to the MHC class-I (Fig. 3). The proteasome can process proteins generating 
peptides with 4 to 20 amino acids, but only the ones with correct length (between 8 to 11 
residues) will be eligible to be associated to the MHC class-I. Those peptides are transported 
from the cytosol to the endoplasmic reticulum (ER) lumen through an ATP-dependent 
transporter for antigen processing (TAP), where they will be assembled to the MHC class-I. 
When the peptide binding is successful the MHC class-I will be released for delivery to the cell 
surface through the secretory pathway (Yewdell et al., 2003).  
The degradation of intracellular proteins is a very specific and tightly regulated process. This 
degradation can be targeted to self proteins, that can be signalized due to misfolding or age-
associated regeneration, or to foreign proteins from virus or other pathogens that are degraded 
and signalized as antigens (Yewdell et al., 2003). This task is ensured by the ubiquitin-
proteasome pathway in two successive steps: 1) ubiquitin-tagging of the substrate through 
covalent binding of multiple ubiquitin molecules and 2) degradation of the tagged protein by the 
26S proteasome complex with release of free and reusable ubiquitin (Glickman & Ciechanover, 
2002). 
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Figure 3 - MHC class I antigen presentation. Cellular proteins are degraded by the proteasome into 
peptides. The transporter for antigen processing (TAP) actively transport the peptides into the lumen of 
the endoplasmic reticulum (ER) where they will be assembled to MHC class-I heterodimers. Peptide 
binding is required for correct folding of the MHC class-I molecules that will then be transported to the 
plasma membrane. At the cell surface, MHC class-I will present the peptides to the immune system 
(Adapted from Yewdell et al., 2003). 
 
Ubiquitin is a highly conserved 76 amino acid polypeptide that covalently attach to target 
proteins through the concerted action of three classes of enzymes, via a three step cascade 
mechanism (Fig.4; Pickart, 2001). First, the ubiquitin-activating enzyme (E1) activates ubiquitin 
in an ATP-dependent reaction to generate a high-energy thiolester intermediate. The activated 
ubiquitin is then transferred to an ubiquitin-conjugating enzyme (E2), forming another thiolesther 
intermediate, that will then specifically bind to an ubiquitin-protein ligase (E3). There are different 
classes of E3. In the case of HECT domain E3s, the ubiquitin is transferred again to the E2 
generating a third high-energy thiolesther intermediate before its transfer to the ligase-bound 
substrate. For RING finger-containing E3, the E3-bound substrate is directly transferred to the 
activated ubiquitin moiety (reviewed in Bosu & Kipreos, 2008; Glickman & Ciechanover, 2002).  
7 
 
 
Figure 4 - Ubiquitin conjugation cascade. Ubiquitin tagging of target proteins is mediated by three 
enzymes: a ubiquitin-activating enzyme (E1), ubiquitin-conjugating enzyme (E2) and ubiquitin protein-
ligase enzyme (E3). ATP-dependent ubiquitin activation by E1 forms a high energy thiolester bond that 
will allow the transfer of the ubiquitin to the E2. Finally, an E3 ligase will mediate the binding of the 
ubiquitin to the target protein. Successive addition of activated ubiquitins can form polyubiquitin chains, 
that can lead the target proteins to different cell fate depending on the length and typology of the chains.  
 
E3s catalyze the covalent attachment of ubiquitin to the substrate, the last step in the 
conjugation process. Generally, the ubiquitin is transferred to a ϵ-NH2 group of an internal Lysine 
(Lys) residue in the substrate to generate a covalent isopeptide bond. Successive addition of 
activated ubiquitin moieties to Lys residues on the previously conjugated ubiquitin C-terminus 
form polyubiquitin chains (Glickman & Ciechanover, 2002; Pickart & Fushman, 2004). 
Depending on the number of ubiquitins and the Lys binding pattern, substrate proteins can 
undergo different fate. Monoubiquitination can lead to cellular targeting or localization signal, but 
does not seem to target proteins to the 26S proteasome. Chains containing at least four 
molecules of Lys-48 linked ubiquitin are necessary for efficient recognition and binding to the 
proteasome. Some evidences point that the hydrophobic interactions of the quaternary structure 
of ubiquitin polymers and the exact spatial relationship between each molecule are critical for 
the ability to target substrates for degradation in the proteasome. Polyubiquitin chains binding 
through Lys-63 instead of Lys-48 seem to play roles in signaling and DNA repair, for instance, 
but probably not in proteasome degradation (reviewed in Glickman & Ciechanover, 2002). 
Ubiquitin can also bind through the other Lys but the mechanisms involved are still not so widely 
studied as for Lys-48 and Lys-63.  
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1.5. E3s - The Cullin-RING ubiquitin ligases 
E3s play a key role in the ubiquitin-mediated proteolytic cascade since they serve as the specific 
recognition factors of the system. They can be classified in two major groups: HECT domain- 
and RING finger-containing E3s, being the largest known class of ubiquitin ligases the Cullin-
RING ubiquitin ligases (CRLs) (reviewed in Bosu & Kipreos, 2008; Glickman & Ciechanover, 
2002). 
CRLs are multisubunit complexes composed by a backbone protein, Cullin, a RING H2 finger 
protein, a substrate-recognition subunit (SRS) and an adaptor subunit that links the SRS to the 
complex (except in the case of CUL3-based CRLs). There are five major categories of Cullins in 
metazoa (CUL1 through CUL5) and a potentially vertebrate-specific class containing CUL7 and 
PARC. Some CRL complexes can form dimers, as CUL1, CUL3 and CUL4-based CRL, in 
contrast to CUL2 and CUL5 CRL complexes that have only been observed as monomers 
(reviewed in Bosu & Kipreos, 2008).  
The activation of CRLs requires the covalent modification of a conserved Lys residue at  the 
Cullin C terminus by the ubiquitin-like protein Nedd8. This process, known as neddylation, is 
required for CRLs activity in vivo and is likely to play a role in the E2 recruitment to the ligase 
complex and stimulation of multiubiquitin chain assembly (Chew & Hagen, 2007). The 
neddylation reaction is similar to the ubiquitination as it involves an heterodimeric E1 (APP-BP-
1/Uba3) that activates Nedd8, the E2 UBC12 that conjugates Nedd8 to the Cullin and DCN1 and 
Rbx1 as E3s. These two E3s might act as a multisubunit E3, though it is possible that Rbx1 is 
the predominant E3 and DCN1 is a cofactor (reviewed in Bosu & Kipreos, 2008).  
The CRLs can be regulated by CAND1, which bind to Cullin proteins and specifically interacts 
with the deneddylated form of the protein, disrupting their interaction with adaptor and SRS, thus 
inhibiting the E3 activity. The COP9 Signalosome (CSN), which is a conserved multisubunit that 
resembles to the 26S proteasome lid complex, can also mediate Cullin deneddylation (Bosu & 
Kipreos, 2008; Chew & Hagen, 2007). CRLs can undergo dynamic cycles of neddylation and 
deneddylation that might be involved with efficient switch between different SRSs, adjust of CRL 
proportions to reflect changes in the cellular levels of SRSs, and activation and stabilization of 
CRL complexes (reviewed in Bosu & Kipreos, 2008).  
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1.6. Plasmodium ubiquitination machinery  
Plasmodium parasites possess the complete machinery that is required for protein 
ubiquitination, including ubiquitin and ubiquitin-like modifiers, E1, E2 and E3 enzymes, and 
deubiquitinases (Ponts et al., 2008). It has been shown that the blood stages of Plasmodium 
spp. possess functional Cullin-RING ligases (Ponts et al., 2008) and that Plasmodium CRL 
function is dependent on neddylation (Artavanis-Tsakonas et al., 2006). Several homolog 
proteins have already been identified from the Plasmodium ubiquitination apparatus with 
highlight to Cullin1 and Nedd8 (Ponts et al., 2008). The relevance of this ubiquitination 
machinery remain to be elucidated but evidences point to an important role in its development 
and successful infection (Ponts et al., 2011).  
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2. Aims 
The recognition of CSP as the immunodominant protein involved in protection induced by 
immunization with irradiated sporozoites lead to a growing interest in understanding the 
mechanisms involved in the process. This subject has mainly been addressed from an 
immunological point of view, trying to dissect how this protein could be used to help to develop 
potential vaccines. Nevertheless, little is known about the precursor mechanisms that could 
allow the CSP to be recognized and targeted for degradation before being presented to the 
immune system. The characterization of the ubiquitination of CSP could be a fundamental step 
to understand how the parasite might achieve an immune evasion strategy, as we hypothesize. 
Genomic and proteomic data from Dr. M. Mota's lab (IMM, Lisbon; Albuquerque et al., 2009 and 
unpublished results) revealed that CRL complexes are down-modulated in cells infected by 
Plasmodium, supporting the hypothesis that the modulation of the UPS could be a strategy to 
avoid recognition by the host immune system. Furthermore, it was also described that 
Plasmodium parasites possess an ubiquitination machinery with functional CRLs. 
Based on this, the aims of the present project are: 
I. To investigate the role of CRLs in the generation of CSP antigenic peptides in the context 
of Plasmodium infection; 
II. To evaluate the CRL activity relevance in Plasmodium intra-hepatic and blood stage 
infection.  
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3. Materials and Methods 
 
3.1. Tissue culture  
The human hepatoma cell line (Huh7) was used for the Plasmodium infection experiments. The 
human embryonic kidney 293 cells (HEK 293T) were used for all the biochemical assays 
(overexpressions and ubiquitination assays). Huh7 cells were cultured and maintained in RPMI 
supplemented with 10% heat-inactivated FBS, 1% HEPES buffer, 1% L-Glutamine, 1% Pen-
Strep and 1% MEM Non-essential amino acids (all from Gibco/Invitrogen). HEK 293T cells were 
cultured and maintained in Dulbecco's Modified Eagle Medium (DMEM; Gibco/Invitrogen) 
supplemented as above. Both cell lines were maintained in incubation conditions of 37ºC and 
5% CO2. 
 
3.2. Parasite lines 
Two transgenic Plasmodium berghei lines were used in this work. Green Fluorescent Protein 
(GFP) – expressing Plasmodium berghei ANKA (PbGFP, parasite line 260 cL2; Franke-Fayard 
et al., 2004) and Luciferase-expressing P. berghei ANKA (PbLuci, parasite line 676 m1cL1; 
Ploemen et al., 2009). Plasmodium sporozoites were freshly obtained by removal and disruption 
of salivary glands from infected female Anopheles stephensi mosquitoes with 21-30 days of 
infection, bred at the insectary of the Instituto de Medicina Molecular (IMM). Dissected salivary 
gland were collected in DMEM, mechanically disrupted and passed through a 70µm pore 
diameter cell strainer. Sporozoite number was determined using a Neubauer chamber 
(haemacytometer) previously rested in a moist chamber for 10minutes, by calculating the 
average of sporozoites per quadrant x 104 x dilution factor x volume. For the studies of blood 
stage infection P. falciparum 3D7 strain was maintained in vitro through culture in red blood 
cells. 
 
3.3. Sporozoite gliding and CSP immunofluorescence  
For sporozoite gliding assay, coverslips were coated with 10µg/ml α-CSP 3D11 antibody (The 
Malaria Research and Reference Reagent Resource Center (MR4)) through 1h incubation at 
37ºC, washed with PBS to remove excess of antibody. 20000 PbGFP sporozoites were added to 
the coverslip in a volume of 300µl and incubated during 30minutes at 37ºC and 5% CO2. 
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Coverslips were fixed with Paraformaldeide (PFA) 4% during 1h at room temperature (RT) or 
overnight at 4ºC, and blocked with 1%BSA in PBS 15minutes at RT. Parasite’ s staining was 
done with 10µg/ml 3D11 antibody, incubating the coverslips for 45minutes followed by PBS 
washes and incubating with a secondary antibody anti-mouse Alexa-488 (Invitrogen - 1:400) for 
45minutes followed by PBS washes. Coverslips were then mounted on microscope slides using 
Fluoromount G solution. Fixed samples were examined under a Zeiss Axiovert 200M inverted 
fluorescence microscope. Image processing was performed with ImageJ software. 
For CSP expression assay, Huh7 cells seeded on coverslips 24h before were infected with 
20000 PbGFP sporozoites. At 6hours post-infection (hpi), 12hpi, 24hpi and 48hpi coverslips 
were washed in PBS and fixed in PFA 4% during 10minutes at RT and washed 3 times with 
PBS. Permeabilization was done with Triton X100 0,5% for 10minutes at RT, followed by PBS 
wash and blocking with 1%BSA in PBS for 30minutes at RT. Immunostaining was done with 
10µg/ml 3D11 (mouse) antibody, incubating the coverslips for 90minutes followed by PBS 
washes and incubating with the secondary antibody anti-mouse Alexa-594 (Invitrogen - 1:400) 
and DAPI (Sigma - 1:1000) for 60minutes followed by PBS washes. Coverslips were then 
mounted on microscope slides using Fluoromount G solution. Fixed samples were examined 
under a Zeiss LSM 510 META confocal point-scanning microscope. Image processing was 
performed with ImageJ software. 
 
3.4. Plasmids 
The plasmids used for the ubiquitination assays were an histidine-tagged ubiquitin construct 
(pCMV-Ub-His; Treier, et al., 1994), six different cullin-RING ubiquitin ligases (CRL) constructs 
purchased from Addgene (Plasmid ref: 19896, 19892, 19893, 19951, 19922, 19895), dominant 
negative Cullin1 (dnCUL1; Chew & Hagen, 2007)  and Plasmodium yoelii circumsporozoite 
protein (CSP) Myc-tagged construct (pCMV-CSP-Myc). pCMV vector was used as an empty-
vector to normalize the amounts of DNA in the reaction. 
 
3.5. DNA transfection 
Reverse transfection of 293T cells was performed using Fugene 6 (Roche) or GeneJuice 
Transfection Reagent (Novagen), following the manufacturer’s instructions. Briefly, 9µl of 
Fugene 6 were mixed with 86µl of DMEM without supplements and incubated for 5minutes at 
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RT. Different amounts of plasmidic DNA (2µg and 2,5µg) were added to the Fugene 6 in a final 
volume of 100µl. The mix was incubated for 45minutes at RT and then added to the freshly 
trypsinized 293T cells. The transfections were done in 6-well plates with 550000 cells/well and 
the medium was changed at 24h post-transfection. When necessary, empty vector was used to 
normalize the total amount of plasmidic DNA.  
 
3.6. Ubiquitination assay 
293T cells were transfected with 1µg of pCMV-Ub-His, 1µg of pCMV-CSP-Myc, and 0,5µg of 
each CRL or dnCUL1 constructs or the necessary amount of empty-vector. When appropriate, 
cells were incubated with 10µM of the proteasome inhibitor MG132 (Calbiochem), added 6h 
before lysis. At 48h post-transfection cells were disrupted in ice-cold lysis buffer containing 
10mM of Tris-HCl (pH 7,5), 150mM of NaCl, 1% of Triton X-100, 10mM of Imidazole, 4M of 
Urea, 1mM of NaF, 0,1mM of Na3VO4, cocktail of protease inhibitor Complete EDTA-free 
(Roche) and H2O. Total cell lysates were prepared with 500µl/well of lysis buffer for 6-well 
plates, followed by a 10minutes ice incubation and centrifugation of 30minutes at 14000rpm at 
4ºC. After recovering the supernatant, 30µl were left aside to serve as total cell lysate (TCL) 
control and the rest was submitted to pull down assay.  
To pull down the ubiquitinated proteins, 50µl/sample of Ni-NTA agarose beads (Qiagen) were 
washed twice with lysis buffer through 1minute centrifugations at 12000rpm and resuspended in 
the same buffer. The beads were added to the samples, sealed with parafilm and incubated for 
2h at 4ºC in gentle agitation. Finally, the beads were centrifuged at 14000rpm for 2minutes and 
slowly and carefully washed in lysis buffer three times. The supernatant was discarded and the 
pellet stored at -80ºC.      
The pull down samples were eluted and denatured at 100ºC for 15minutes in Laemmli’s Buffer 
(Tris-HCl pH6,8, SDS 10%, glycerol and bromophenol blue) 6x with 5% β-Mercaptoethanol and 
centrifuged 2minutes at 14000rpm. TCL samples were denatured at 100ºC for 5minutes with 
Laemmli’s Buffer 6x with 5% β-Mercaptoethanol. Both were further analyzed by Western Blot.  
 
3.7. Western blot 
Western blots were done with MiniProtean Tetra Cell equipment (BioRad).1,5mm Tris-glycine 
SDS-PAGE resolving and stacking gels were prepared in percentages between 5% and 12% 
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SDS depending on the expected protein molecular weight (Maniatis, et al., 1982). Gels were 
loaded with 12µl of TCL samples, 20µl of pull down samples and 5µl of molecular weight marker 
(Precision Plus Protein™ Dual Color Standards - BioRad or ColorBurst™ Electrophoresis 
Marker - Sigma). Running buffer was prepared with Tris, Glycine, SDS and H2O. The gels were 
run at constant voltage of 100V until samples entered the resolving gel and then increased to 
180V. For the transference to the nitrocellulose transfer membrane (BioTrace™ NT, Pall), a 
transfer buffer with Tris, Glycine, Ethanol and H2O was used. The gel and nitrocellulose 
membranes were placed between two layers of filter paper and blotting pads. The transfer was 
processed at constant amperage of 200mA at 4ºC for 1h45, or overnight decreasing amperage 
to 30mA after 2h in the case of pull down experiments.  
Blocking of the nitrocellulose membranes was done in a 5% powdered milk (Molico, Nestlé) 
solution in PBS with 0,05% Tween-20. The membranes were incubated in blocking solution 
during 1h at RT and in slow agitation.  
Primary antibody incubation was done overnight at 4ºC in slow agitation, with anti-α Tubulin ( 
mouse monoclonal IgG1, clone DM1A - Sigma - 1:1000), anti-P. yoelii CSP (2F6 mouse 
monoclonal, Bruna-Romero et al., 2004 - 1:1000), anti-c-Myc (mouse monoclonal 9E10 – Sigma 
- 1:1000),. Nitrocellulose membranes were washed three times in PBS Tween 0,05% in rapid 
agitation during 15minutes.  
Secondary antibody incubation was done at RT during 1h in slow agitation, with anti-mouse 
HRP (goat, anti-mouse HRP - Santa Cruz - 1:5000; 1:7000) or anti-rabbit HRP (donkey, anti 
rabbit HRP - GE healthcare -1:5000; 1:7000), followed by three washes with PBS Tween 0,05% 
in rapid agitation. 
Detection of the immunoblot was done incubating the membranes 5minutes in dark with 
detection solution (Supersignal West pico chemiluminescent substrate HRP – ThermoScientific 
or ImmunStar WesternC Chemiluminescence Kit - BioRad) and proceeding to the exposure and 
developing of films (Fuji medical X-ray film, Fujifilm).  
 
3.8. In vitro P. berghei liver stage infection assessment through luminescence 
Huh7 cells were seeded 24h prior infection in an average of 7000 cells/well for 96-well plates. 
For this assay, PbLuci sporozoites were used to infect the cells in an average of 10000 
sporozoites/well. Cells and parasites were further centrifuged for 5minutes at 3000rpm and 
incubated at 37ºC and 5% CO2 for 48h. The medium was changed 24hpi.  
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After 48hpi cells were processed for analysis with the Firefly Luciferase Assay Kit (Biotium). The 
cells were washed in PBS and incubated for 20minutes in agitation with 75µl/well of Lysis Buffer.  
After 5minutes centrifugation at 3000rpm, 30 µl of the lysate was transferred to a white Nunc™ 
F96 MicroWell™ Plate (Thermo Scientific) and the luciferase reaction performed. 50 µl of D-
Luciferin reconstituted in Firefly Luciferase assay buffer (FLAB) was added to each cell lysate 
and luminescence was immediately read in a plate reader (InfiniteM200, software Tecan i-
control) using 100ms of integration time. 
Cell confluence was also determined through Alamar Blue (Invitrogen). Alamar blue (1:20) was 
incubated with cells during 1h30-2h and fluorescence read through plate reader by 530nm 
excitation and 590nm emission wavelengths, gain of 90, 25 flashes and 20µs integration time. 
Cell confluence was assessed immediately before infection and at 48hpi. 
 
3.9. Plasmodium falciparum in vitro culture and flow cytometry analysis 
P. falciparum 3D7 strain was cultured in malaria culture medium (MCM) medium composed of 
RPMI supplemented with 0,1% Gentamycin, 1% L-Glutamine, 2,4% HEPES buffer and 10% of 
10x Albumax II solution (supplemented with 5,2g RPMI with L-Glutamine/without NaHCO3, 500µl 
Gentamycin, 2,98g HEPES, 1,67g NaHCO3, 1g Glucose, 0,1g Hypoxanthine and 25g Albumax II 
(Gibco) for 500ml solution). The culture was maintained at 37ºC and 5% CO2.   
The cultures were synchronized 48h prior experiment  through 15minutes incubation in 5% 
sorbitol in order to have all the parasites as ring forms. 2,5% of fresh red blood cells (RBC) 
suspension were added to a 1% parasitemia culture (percentage of infected RBC/ total RBC) in 
a total volume of 600µl for 24-well plates. Cells were incubated at 37ºC and 5% CO2 and 
infection was followed until 72h pi.  
At time point 0h and then every 6h (until 72h of incubation), 5µl of previously resuspended RBC 
samples were incubated in 50µl of SYBRGreen (Invitrogen) during 20minutes at RT in dark, 
resuspended in 900µl of PBS and analyzed through flow cytometry. Flow cytometry analysis 
was done in a benchtop flow cytometer, CyFlow® (Partec, Münster, Germany), with a 488nm 
blue laser, with detectors for forward scatter (FSC), side scatter (SSC), fluorescence FL1 (band 
pass 535/45 nm filter) and FL3 (long pass 620 nm filter), as well as a detector for depolarized 
side scatter. 100000 events were analyzed for each sample. 
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3.10. Inhibitor of NEDD8-activating enzyme – MLN4924 
MLN4924, inhibitor of NEDD8-activating enzyme (Millennium Pharmaceutics, Inc.; Soucy et al., 
2009) was resuspended in Dimethyl Sulfoxide (DMSO) in a stock concentration of 10mM.This 
compound was used for in vitro assays using P. berghei and P. falciparum parasites to assess 
its effect in both liver and blood stage of infection, respectively. 
P. berghei liver stage infection was assessed through luminescence and using Huh7 cells 
infected with PbLuci (as previously determined). Different concentrations of MLN4924 in a range 
from 5 µM to 0,01 µM were prepared in RPMI complete medium and added to the cells at 2h 
post-infection. Triplicates were done for each condition and DMSO was used as a control. 
Luciferase assay was performed at 48h pi. 
P. falciparum blood stage infection was assessed through flow cytometry (as previously 
described) using MLN4924 at 1µM, 10µM, 50µM and 100µM concentrations. Samples were 
taken at the moment of infection, 6hpi, 12hpi, 24hpi, 30hpi, 48hpi and 72hpi. At the same time 
3µl of each sample were prepared in slides to follow infection through microscopy. Slides were 
fixed in methanol and stained 20minutes with Giemsa (Merck), and washed in water. Fixed 
samples were examined under a Leica DM2500 brightfield microscope equipped with a color 
camera. Image processing was performed with ImageJ software. 
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4. Results and discussion 
 
4.1. Role of CRL in the generation of CSP antigenic peptides 
 
4.1.1. Circumsporozoite protein expression 
The first stage of a malaria infection occurs in the liver. After being deposited in the skin, through 
the bite of an infected mosquito, Plasmodium sporozoites enter the circulatory system and travel 
to the liver where they will infect and develop inside the hepatocytes. During the process of liver 
invasion, sporozoites migrate through several cells breaching their plasma membrane and 
leaving behind trails of some of their surface proteins. CSP is the major surface protein of 
Plasmodium sporozoites (Mota & Rodriguez, 2002), and it has been shown to play a key role in 
infection of both mosquito salivary glands and the vertebrate host, mediating sporozoite 
adhesion to target cells. During the process of migration, CSP that is normally uniformly 
distributed in the sporozoite surface, moves from the anterior to the posterior end of the 
sporozoite, where it is shed and deposited in a trail (Mota & Rodriguez, 2002).  
In figure 5, we can observe the circular trails of CSP (in green) left by the motile Plasmodium 
sporozoites during the process of gliding motility. The sporozoites present an elongated form 
and appear with the higher intensity (Fig. 5). These results were achieved through a technique 
that consists in plating sporozoites on coverslips pre-coated with an antibody for CSP with 
subsequent immunostaining against the same protein, and are in accordance with the 
description of CSP trails in Mota & Rodriguez (2002).    
 
 
Figure 5 – Plasmodium sporozoites leave a CSP trail 
during gliding. P. berghei sporozoites were plated in anti-CSP 
pre-coated coverslips, fixed and immunolabeled for CSP 
(green). Scale bar, 10µm.  
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To follow the expression of CSP throughout the infection, CSP immunostaining was performed 
in in vitro infected cells fixed at four different hours post-infection (hpi) time points. We can 
observe the expression of CSP on the sporozoite at 6hpi (Fig. 6A;E) that is maintained through 
the later time points after infection of an hepatoma cell when the parasite start to develop into 
exo-erythrocytic forms (EEF) (Fig. 6). In this stage, the staining is observed in the 
parasitophorous vacuole (Fig.6 D;H). Therefore, it is possible to conclude that CSP is expressed 
on the surface of the Plasmodium parasite throughout the liver stage infection as described in 
Hollingdale et al. (1983). 
 
 
 
 
 
CSP has been also extensively studied as a vaccine candidate and to date is the only 
Plasmodium protein shown to confer protection to immunized individuals. It was shown that CSP 
can be presented as an antigen by the MHC class-I complex being able to stimulate CD8+ T 
cells. This process depends on the proteasome degradation of CSP (Bongfen et al., 2007), that 
must be first tagged with ubiquitin. Therefore, ubiquitination of CSP is a fundamental step for the 
Plasmodium parasite recognition by the host immune system.  
Figure 6 – CSP is expressed throughout P. berghei liver stage infection. Huh7 cells 
infected with GFP expressing P. berghei (green) were fixed at 6 hours (A, E), 12 hours (B, F), 
24 hours (C, G) and 48 hours post-infection (D, H). Samples were immunostained for CSP (red 
in A-D; grey in E-H) and nuclei (blue). Merged images (A-D).  Scale bar, 10µm.  
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4.1.2. The role of the Cullin-RING E3 ligases in CSP ubiquitination         
CRLs are the largest group of E3 ligases, which are key players in the specific recognition of 
substrates for the tightly regulated ubiquitin-mediated pathway (Bosu & Kipreos, 2008). CRLs 
are multi-subunit complexes that achieve the specific recognition of substrates through the 
combination of different backbones (Cullins) and adaptor molecules (Bosu & Kipreos, 2008). 
These different combinations are based in six different Cullins that will give different affinities to 
the complex and consequently lead to the ubiquitination of different substrates (Bosu & Kipreos, 
2008). Preliminary data obtained by proteomic studies in the host laboratory demonstrate that 
three of six Cullin-RING ligase complexes (Cullin1, Cullin2 and Cullin4A, and their respective 
adaptor proteins, Skp-1, Elongin-B and DDB1) were found to be down modulated in Plasmodium 
infected cells (unpublished). Based on this, we hypothesize that in Plasmodium infected cells the 
presentation of antigen-MHCI complexes could be compromised, constituting the backbone of 
an immune-evasion strategy. Therefore, we proposed to investigate the participation of the 
CRLs in this immune evasion mechanism, in particular to test whether a specific CRL complex 
promotes CSP ubiquitination. This was assessed through the overexpression of the different 
CRL's backbones, the Cullins. 
An assay overexpressing the protein of interest, an histidine-tagged ubiquitin and an E3 ubiquitin 
ligase in 293T cells followed by a nickel-nitrilotriacetic acid (Ni-NTA) pull down was the base for 
these experiments. This protocol is based in the high affinity of Ni-NTA beads and histidine, 
allowing the recovery of the histidine tagged ubiquitin, respectively bound to its target proteins. 
This procedure enables the recovery of protein complexes making it a valuable tool to study 
protein-protein interactions. Using this approach we addressed the implication of the Cullin-
RING E3 ligases in the ubiquitination of CSP co-expressing CSP, his-tagged ubiquitin and each 
of the six different Cullins (CUL 1, 2, 3, 4A, 4B and 5). The levels of CSP poly-ubiquitination in 
the presence of the different CRLs were analyzed by Western Blot. 
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 a) Characterization of CSP constructs 
The coding sequence for circumsporozoite protein of Plasmodium yoelii (Py), previously cloned 
and available in the lab, was sub-cloned into a pCMV-myc tagged vector. Due to the commercial 
unavailability of an antibody specific for PyCSP we tested the possibility of using the Myc-tag to 
detect the CSP overexpression by western blot. Four out of the six clones tested correctly 
expressed CSP (CS0, 1, 3, 5 - Fig. 7 ). The cloned vectors were also verified by sequencing. 
The western blot analysis (Fig. 7) shows that CSP has a molecular weight of approximately 
75KDa when expressing the Myc tag. These expression results are reproducible using both the 
specific antibody for CSP (Fig. 7A) and an antibody specific for the Myc-tag (Fig. 7B). Clone 
number 0 (CS0) was selected to pursue the experiments.  
 
 
 
 
 
 
 
  
 
  
Figure 7 – CSP overexpression and detection with a specific antibody for the myc-tag. 
HEK 293T cells were transfected with several clones from pCMV-CSP-Myc plasmids, lysed and 
immunoblotted with anti-CSP (A), anti-cMyc (B) and anti-αTubulin (αTub) as loading control (C, 
D) - C correspond to the CSP blot (A), D correspond to the cMyc blot (B). Blot exposition times 
(exp): A- 5minutes; B- 2minutes; C- 5minutes; D- 30seconds.   
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 b) CRL involvement in CSP poly-ubiquitination: pull down assays  
To characterize the involvement of CRL complexes in the poly-ubiquitination of CSP we 
performed pull-down assays as described above, although some previous technique 
optimizations were required.   
The DNA amount of pCMV-CSP-myc that was used for transfection in some preliminary assays 
(0,5µg) appeared to be insufficient to be efficiently detected through western blot, so it was 
increased to 1µg which seemed sufficient to overcome this problem (data not shown). Also, to 
further optimize the experimental conditions a proteasome inhibitor (MG132) was added to the 
protocol. The use of this compound improves the recovery of the poly-ubiquitinated proteins 
targeted for proteasomal degradation. In these conditions the total cellular lysate (TCL) is 
enough to illustrate the CSP poly-ubiquitination patterns.  
Figure 8A shows the results of the pull down assay analyzed by western-blot using an antibody 
specific for the Myc tag. The first and second lanes represent negative control using only 
ubiquitin and positive control using CSP, respectively. The third lane demonstrates the result of 
the CSP endogenous ubiquitination consequence of overexpressing CSP and ubiquitin together. 
Lanes 4 to 9 represent the outcome of overexpressing the different Cullin constructs in addition 
to ubiquitin and CSP. Figure 8B represent the results of the blot of a total cellular lysate (TCL) 
from the same samples, collected before the pull down, and a loading control using an antibody 
specific for αTubulin. Figure 8C represent an improved TCL result from an independent 
experiment. 
The results of three independent experiments show that all Cullins, although is less clear for 
Cullin 5, seem to promote CSP poly-ubiquitination to some extent when compared to the levels 
of ubiquitination in the absence of the E3 ligase (Fig. 8B, C - lane3). However, clear differences 
can be seen for the ubiquitination of CSP in the presence of CUL1 and CUL4B from the rest, as 
they show a stronger poly-ubiquitination ladder (Fig. 8C). This is due to the formation of different 
sizes of poly-ubiquitin chains that by the addition of each ubiquitin molecule will add 8,5kDa to 
the initial molecular weight.  
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 c) Involvement of Cullin1 in CSP poly-ubiquitination: the effect of dnCUL   
In order to confirm the implication of the Cullin1 in the ubiquitination of CSP we overexpressed a 
mutant form of this protein that is unable to constitute a functional CRL due to the lack of Roc1-
binding and neddylation sites. This dominant negative form of Cullin1 (dnCUL1) is, however, still 
able to bind to the adaptor proteins and substrate recognition subunits (Chew & Hagen, 2007). 
We repeated the pull down experiment overexpressing in parallel the CUL1 and dnCUL1 
Figure 8 – CSP poly-ubiquitination assay catalyzed by different CRLs. 293T cells were 
transfected to overexpress pCMV-CSP-Myc, ubiquitin-6His and six different Cullins, and 
submitted to pull down (PD) of the his-tagged ubiquitin. Both PD (A) and TCL (B, C) samples 
were submitted to western blot using an antibody for the myc-tag. TCL was also blotted with 
αTubulin as a loading control (B, C). C is an improved replica of B (independent experiment). 
Exp: A- 10seconds; B, C-30seconds. 
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constructs, so it would be possible to compare and evaluate the role of CUL1 in the poly-
ubiquitination of CSP. 
The results indicate that while CSP poly-ubiquitination is promoted in the presence of the wild 
type form of Cullin1 (Fig. 9A, lane 4), the same does not happen with the dominant negative 
form of Cullin1. In this case, the poly-ubiquitin ladder (Fig. 9A, lane 5) is more similar to the 
control without cullins (Fig. 9A, lane 3). The same is evident on the TCL results that also seem to 
point to a greater expression when using the wild type CUL1, comparing with dnCUL and the 
endogenous control (Fig. 9B - lane 5 and 3, respectively). A way to improve the analysis of these 
results would be to quantify the western blot bands intensity so it would be easier to compare 
their relative expression levels.  
In conclusion, despite the preliminary nature of these results, they seem to indicate that CUL1 is 
indeed promoting CSP poly-ubiquitination. Together with the proteomic data that presented 
CUL1 and its adaptor as down modulated proteins in infected cells, these results seem to 
support the hypothesis of the modulation of the host UPS as a strategy to avoid recognition by 
the immune system.  
 
 
 
 
 
Figure 9 – Contribution of CUL1 in CRL complexes in CSP ubiquitination. 293T cells were 
transfected to overexpress pCMV-CSP-myc, ubiquitin-6His and wild type or dominant negative 
form of CUL1, and submitted to pull down of the his-tagged ubiquitin. Both PD (A) and TCL (B) 
samples were submitted to western blot using an antibody for the myc-tag. TCL was also blotted 
with αTubulin as a loading control (B). Exp: A- 2minutes; B- 2minutes (Myc) / 10seconds (Tub). 
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It would be interesting to pursue these studies using the dominant negative forms of the other 
Cullins, mainly the CUL4B that also seem to promote a distinctive CSP poly-ubiquitination 
profile. Another way to further proceed would be to try to identify other important players in the 
CSP poly-ubiquitination. To achieve this we could use co-immunoprecipitation, which is a 
technique to identify protein-protein interactions based in antibody affinity. This would allow to 
recover proteins interacting with CSP, which could be identified through mass spectrometry. A 
better understanding of the players involved in the CSP ubiquitination process could also give 
another insight about the importance of the CRLs.   
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4.2. CRL activity relevance in Plasmodium infection 
 
It has been shown that the blood stages of Plasmodium spp. possess functional Cullin-RING 
ligases (Ponts et al., 2008). Furthermore, Plasmodium CRL function is also dependent on the 
neddylation activity (Artavanis-Tsakonas et al., 2006). Hypothesizing that the parasite CRLs 
could be used as targets for an anti-malarial strategy, we used a recently developed compound 
described to be a potent and selective inhibitor of Nedd8 activating enzyme (NAE) to assess 
this. MLN4924 is a small molecule that binds selectively to NAE preventing the assembly and 
activation of the CRL complex, leading to a defective E3 ligase that is unable to promote 
ubiquitination of substrates (Soucy et al., 2009).  
 
4.2.1. Neddylation inhibition effect in Plasmodium liver stage infection  
To assess the effect of the inhibition of CRLs neddylation in the liver infection context, we setup 
a luminescence assay using Huh7 cells and Luciferase-expressing P. berghei parasites. The 
cells were infected 24h after the seeding and the compound added 2-3hpi, to avoid interference 
with the invasion step. A wide range of concentration was tested starting from 0,01µM until 5µM, 
measuring infection at two different time points, 24h and 48hpi. Cell confluency was evaluated 
before infection to guarantee that all the wells were comparable (not shown), and at the end of 
the experiment. DMSO, the solvent used as vehicle for the drug reconstitution, was used as 
control and all the results were normalized to 0,01µM DMSO. 
The results of four independent experiments (Fig. 10) indicate that although the higher 
concentrations of the compound (5µM and 1µM) have a slight effect on cell viability after 48h of 
incubation (blue circles on the plot in Fig. 10B), there is no significant effect in Plasmodium 
infection levels at 24h or 48hpi when the cells are treated with MLN4924, as evidenced by the 
orange bars when compared to the control (grey bars) in figures 10A and B. 
These experiments show that there seems to be no effect in the outcome of Plasmodium liver 
infection upon neddylation inhibition by the use of MLN4924. Nevertheless, a good approach to 
confirm these results would be to follow these parasites by microscopy to look for potential 
morphological alterations that might give some evidence about other indirect effects of the drug 
in the liver stage. 
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Figure 10 – Effect of neddylation inhibition in Plasmodium berghei liver stage infection. 
Infection analysis through luminescence of P. berghei infected Huh7 cells submitted to 
treatment with MLN4924 or drug vehicle (DMSO) as control, in concentration ranging from 
0,01µM to 5µM. The infection levels were determined at 24h (A) or at 48hpi (B) and normalized 
to 0,01µM DMSO. In both experiment cell confluency was measured prior to the luminescence 
reading. 
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4.2.2. Neddylation inhibition effect in Plasmodium blood stage infection  
Since no effects were seen upon the liver infection, we wondered whether MLN4924 could have 
an effect in the blood stage of infection. So far, the description of NEDD8-like enzyme as well as 
CRL-like complexes has only been associated to the blood stages forms of Plasmodium 
falciparum (Artavanis-Tsakonas et al., 2006). Therefore, we designed an experiment using in 
vitro cultures of P. falciparum 3D7 to test the effect of MLN4924 in blood stage infection through 
flow cytometry. This approach allowed following the parasite numbers throughout infection, 
using SYBRgreen DNA marker, and parasite maturation using a detector of light depolarization. 
This measure is based in the hemozoin crystal formation, a malaria pigment which content 
increases proportionally to the maturation of the parasite (Rieckmann, 1982) and that can be 
plotted through the measurement of the depolarization of the light resulting from its incidence in 
the crystals (Frita et al., 2011). 
Fresh red blood cells were incubated with a ring form synchronized P. falciparum culture and 
infection was followed for 72h. The drug was added at the beginning of the culture in 
concentrations ranging from 1µM to 100µM. DMSO was used as control. The lowest  
concentrations of the compound (1µM and 10 µM) didn’t have any effect upon infection as their 
profile followed almost exactly the one from the drug free control (data not shown and Fig. 11A 
and B). The 100µM concentration exhibited a strong effect blocking parasite development. As 
observed in figure 11C, the cultures of P. falciparum in the presence of drug at this 
concentration completely arrest in ring forms or small and deformed parasites throughout the 
72h (100 µM ; Fig. 11C). However, the corresponding concentration of DMSO (1%) seem to 
show some toxicity by itself, as parasite development is also arrested when they reach the 
schizont form (48h, Fig. 11B), compromising the MLN4924 results. Nevertheless, it is also 
possible to see effects with the 50µM concentration of the drug, which show a significant 
maturation delay (50 µM; Fig. 11B), most likely accompanied with impaired replication and 
release of the merozoites, as the parasitemia didn’t change between 48h and 72h (Fig. 11A).       
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Figure 11 – Effect of neddylation inhibition in Plasmodium falciparum blood stage 
infection.  Flow cytometry analysis based on parasitemia (A) and light depolarization (B) of 
infected red blood cells subjected to treatment with 10µM, 50µM and 100µM of MLN4924 or 
DMSO. Blood smears stained with Giemsa (C) from samples treated with 50µM and 100µM of 
MLN4924, DMSO 0,5% and 1% or drug free. Overall parasite forms in drug free conditions: 6h 
rings; 12h-24h trophozoites; 30h schizonts; 48h rings; 72h trophozoites. 
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The MLN4924 effect in the blood stage suggest that the CRLs could be a new specific target to 
try to develop antimalarial drugs. Some compounds that addressed the UPS were already tested 
in the context of malaria infection, like MLN-273 which is a proteasome inhibitor that was shown 
to block P. falciparum blood stage at an early ring stage and to inhibit P. berghei liver stage 
progression (Lindenthal et al., 2005). Despite these promising results, it seems that this 
compound didn't qualify to proceed to further studies.  
One of the reasons to choose MLN4924 for our study was that the compound was already FDA 
approved, and although it was being studied in the cancer context, this could give some 
advantage in comparison to drugs that are being tested for the first time. Besides, another 
advantage was the high specificity toward the CRL inhibition, contrarily to previous studies that 
targeted the proteasome. However, in the context of P. falciparum blood stage infection, 
MLN4924 have to be used in really high concentrations to present a visible effect comparing 
with other drugs. The lowest concentration where it is possible to see an effect in parasite 
development or replication rate in our studies stand between 10µM and 50µM, which is really 
high comparing to MLN-273, for instance, that presented effects with 100nM (Lindenthal et al., 
2005). The majority of the compounds that are potential candidates or already used as malaria 
drugs present effects with concentrations in the nano-molar range (Touré et al., 2008), therefore 
MLN4924 doesn't seem to be potent enough to compete with this class of molecules. However 
these results open a new perspective on using CRLs as potential targets to develop new 
antimalarial compounds.  
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5. Conclusion 
 
Our results provide a good evidence about the participation of Cullin-RING ligases in the 
ubiquitination of circumsporozoite protein, in particular about the involvement of Cullin1. These 
observations support the hypothesis that Plasmodium can modulate the host UPS as an 
immune evasion strategy, since additionally to the previous observation of the down modulation 
of CUL1 in infected cells, it seems that this particular Cullin is actively involved in the CSP 
ubiquitination. Therefore, if CSP ubiquitination is in fact down modulated in infected cells, the 
mechanism of CSP antigen presentation by MHC classe-I complexes and consequently the 
recognition and targeting of infected cells by specific CD8+ T cells could be compromised.  
Furthermore, we conclude that UPS is an essential pathway for Plasmodium development 
during the blood stage of infection, as we could actively delay or arrest the parasite maturation 
when interfering with the CRL activity using MLN4924. Although MLN4924 is not potent enough 
to be considered as a potential antimalarial compound, it demonstrated that the CRL must 
indeed play an important role in the parasite development, emerging as a specific new target for 
the development of new antimalarial drugs. 
In conclusion, Cullin-RING ligases and the ubiquitin-proteasome system appear to be of great 
relevance in the malaria infection context for both mammalian host and Plasmodium parasite. It 
is tempting to hypothesize that Plasmodium has recognized the value of this pathway and 
managed to take advantage of the host UPS to create a more hospitable environment to 
reproduce itself. Further understanding of the mechanisms behind this strategy would be 
fundamental to try to overcome this Plasmodium parasite advantage for the establishment of a 
productive malaria infection. 
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